AZD-0424

an oral inhibitor of Src and ABL1

Also Known As:

1-(4-(2-((4-((6-Chloro(1,3)dioxolo(4,5-b)pyridin-7-yl)amino)-5-isopropoxy-7-quinazolinyl)oxy)ethyl)-1-piperazinyl)ethanone; 7-(2-(4-acetylpiperazin-1-yl)ethoxy)-N-(6-chloro(1,3)dioxolo(4,5-b)pyridin-7-yl)-5-isopropoxyquinazolin-4-amine; AZD0424; Ethanone, 1-(4-(2-((4-((6-chloro-1,3-dioxolo(4,5-b)pyridin-7-yl)amino)-5-(1-methylethoxy)-7-quinazolinyl)oxy)ethyl)-1-piperazinyl)-

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - AZD-0424: 3

Experts

1.	Brunton, Valerie G: 1 article (01/2022)
2.	Carragher, Neil O: 1 article (01/2022)
3.	Dawson, John C: 1 article (01/2022)
4.	Frame, Margaret: 1 article (01/2022)
5.	Macleod, Kenneth: 1 article (01/2022)
6.	Muir, Morwenna: 1 article (01/2022)
7.	Munro, Alison: 1 article (01/2022)
8.	Timpson, Paul: 1 article (01/2022)
9.	Williams, Robert J: 1 article (01/2022)
10.	Roskoski, Robert: 1 article (04/2015)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "We show that AZD0424 potently inhibits the phosphorylation of tyrosine-419 of SRC (IC50 ~ 100 nm) in many cancer cell lines; however, inhibition of cell viability, via a G1 cell cycle arrest, was observed only in a subset of cancer cell lines in the low (on target) micromolar range. " 01/01/2022 - "Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment." 01/01/2022 - "We profiled the changes in intracellular pathway signalling in cancer cells following exposure to AZD0424 and other targeted therapies using reverse-phase protein array (RPPA) analysis. " 04/01/2015 - "The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clinical trials for a variety of solid tumors including breast and lung cancers. "
2.	Lung Neoplasms (Lung Cancer) 04/01/2015 - "The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clinical trials for a variety of solid tumors including breast and lung cancers. "
3.	Lymphoma (Lymphomas) 10/01/2007 - "We here demonstrate that three newly developed dual selective Src/Abl kinase inhibitors (SrcK-I) (AZM559756, AZD0530 and AZD0424) are able to induce apoptosis and cell cycle arrest in BCR-ABL, c-KIT and platelet-derived growth factor-negative lymphoma cell lines. "

Related Drugs and Biologics

1.	saracatinib
2.	Mitogen-Activated Protein Kinase Kinases (MEKs)
3.	Proteins (Proteins, Gene)
4.	Platelet-Derived Growth Factor
5.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Therapeutics